Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharmacogenet Genomics
2010 Feb 01;202:112-20. doi: 10.1097/FPC.0b013e328335b02d.
Show Gene links
Show Anatomy links
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC
,
Kwan WS
,
Shallcross V
,
Chaikan A
,
Liptrott N
,
Egan D
,
Sora ES
,
James CE
,
Gibbons S
,
Bray PG
,
Back DJ
,
Khoo SH
,
Owen A
.
???displayArticle.abstract???
OBJECTIVE: OATP1B1 and OATP1B3 are major hepatic drug transporters whilst OATP1A2 is mainly located in the brain but is also located in liver and several other organs. These transporters affect the distribution and clearance of many endobiotics and xenobiotics and have been reported to have functional single nucleotide polymorphisms (SNPs). We have assessed the substrate specificities of these transporters for a panel of antiretrovirals and investigated the effects of SNPs within these transporters on the pharmacokinetics of lopinavir.
METHODS: SLCO1A2, SLCO1B1 and SLCO1B3 were cloned, verified and used to generate cRNA for use in the Xenopuslaevis oocyte transport system. Using the oocyte system, antiretrovirals were tested for their substrate specificities. Plasma samples (n=349) from the Liverpool therapeutic drug monitoring registry were genotyped for SNPs in SLCO1A2, SLCO1B1 and SLCO1B3 and associations between SNPs and lopinavir plasma concentrations were analysed.
RESULT: Antiretroviral protease inhibitors, but not non-nucleoside reverse transcriptase inhibitors, are substrates for OATP1A2, OATP1B1 and OATP1B3. Furthermore, ritonavir was not an inhibitor of OATP1B1. The 521T>C polymorphism in SLCO1B1 was significantly associated with higher lopinavir plasma concentrations. No associations were observed with functional variants of SLCO1A2 and SLCO1B3.
CONCLUSION: These data add to our understanding of the factors that contribute to variability in plasma concentrations of protease inhibitors. Further studies are now required to confirm the association of SLCO1B1 521T>C with lopinavir plasma concentrations and to assess the influence of other polymorphisms in the SLCO family.
Back,
Therapeutic drug monitoring in HIV infection: current status and future directions.
2002, Pubmed
Back,
Therapeutic drug monitoring in HIV infection: current status and future directions.
2002,
Pubmed
Barreiro,
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
2007,
Pubmed
Boffito,
Host determinants of antiretroviral drug activity.
2005,
Pubmed
Briz,
Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin.
2003,
Pubmed
,
Xenbase
Campbell,
Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.
2004,
Pubmed
Chandra,
The complexities of hepatic drug transport: current knowledge and emerging concepts.
2004,
Pubmed
Choi,
Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
2008,
Pubmed
Chung,
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
2005,
Pubmed
Cui,
Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma.
2003,
Pubmed
Dickinson,
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
2005,
Pubmed
Dieleman,
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.
1999,
Pubmed
Ernest,
Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
2005,
Pubmed
Fan,
The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1.
2008,
Pubmed
Fichtenbaum,
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
2002,
Pubmed
Fletcher,
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
2004,
Pubmed
Haas,
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
2005,
Pubmed
Haas,
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
2004,
Pubmed
Hamada,
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
2008,
Pubmed
Hirano,
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.
2004,
Pubmed
Ho,
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.
2007,
Pubmed
Hsiang,
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
1999,
Pubmed
Ieiri,
SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
2007,
Pubmed
Kalliokoski,
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
2008,
Pubmed
Khoo,
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support.
2006,
Pubmed
Kim,
Organic anion-transporting polypeptide (OATP) transporter family and drug disposition.
2003,
Pubmed
Kivistö,
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
2007,
Pubmed
Kullak-Ublick,
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
2001,
Pubmed
,
Xenbase
Kullak-Ublick,
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
1995,
Pubmed
,
Xenbase
Lau,
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
2007,
Pubmed
Lee,
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.
2005,
Pubmed
Link,
SLCO1B1 variants and statin-induced myopathy--a genomewide study.
2008,
Pubmed
Maeda,
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
2006,
Pubmed
Marzolini,
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
2001,
Pubmed
Owen,
Pharmacogenetics of HIV therapy.
2006,
Pubmed
Owen,
Pharmacogenetics of antiretroviral agents.
2008,
Pubmed
Pai,
Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
2004,
Pubmed
Pasanen,
Global analysis of genetic variation in SLCO1B1.
2008,
Pubmed
Pasanen,
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
2006,
Pubmed
Profit,
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
1999,
Pubmed
Sharifi,
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
2008,
Pubmed
Siccardi,
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
2008,
Pubmed
Smith,
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
2007,
Pubmed
,
Xenbase
Sturm,
The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain.
1988,
Pubmed
Su,
Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
2004,
Pubmed
,
Xenbase
Tamai,
Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.
2000,
Pubmed
Tirona,
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
2001,
Pubmed
Veldkamp,
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
2001,
Pubmed
Wyen,
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
2008,
Pubmed
